PAR •
Healthcare •
Biotechnology •
Quote as of 09/11/2026 17:35
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangePAR
Market Capitalization8,515.97 mln
Float86.23 mln
Earnings Date09/14/2026
1-Year Forecast
139
Strong upside
Relative Strength
93
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-124
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
ABIVAX is a French biotech company founded in 2013 that works on treatments for long-term inflammatory conditions such as ulcerative colitis and Crohn's disease. Its main drug, obefazimod, is currently being tested in late-stage clinical trials. The company operates by targeting the body's own immune system to reduce harmful inflammation in affected patients.
